Physician profile
Edith M Utley
NPI 1003951658
$14,598.66
in general payments reported to CMS, 2019-2025
32 companies · $2,913 in 2025
The $2,913 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,589 · 2022: $3,079 · 2023: $3,714 · 2024: $3,303 · 2025: $2,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,800 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,799.65 |
| Education | $130.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,705.80 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $2,705.40 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,086.42 | 2021-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $848.10 | 2021-2025 | Ofev, Jascayd, Stiolto Respimat |
| Insmed, INC. | $714.67 | 2021-2025 | Arikayce |
| Genzyme Corporation | $598.23 | 2022-2025 | |
| Mylan Specialty L.P. | $557.27 | 2021-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $468.44 | 2021-2025 | Acthar |
| Grifols USA, LLC | $449.79 | 2021-2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $439.47 | 2021-2025 | Tyvaso, Tyvaso |
| Ani Pharmaceuticals, INC. | $369.01 | 2023-2025 | Purified Cortrophin Gel |
| Harmony Biosciences LLC | $365.53 | 2021-2024 | Wakix |
| Amgen INC. | $304.56 | 2022-2025 | Tezspire |
| Electromed, INC. | $256.87 | 2022-2023 | Smartvest |
| Merck Sharp & Dohme LLC | $242.01 | 2021-2024 | Keytruda, Winrevair |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $233.19 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $219.56 | 2021-2024 | Glassia |
| Axsome Therapeutics, INC. | $202.41 | 2022-2025 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $154.67 | 2021-2024 | Opsumit, Uptravi |
| Philips North America LLC | $118.77 | 2022-2024 | (Ak6) Vest Therapy |
| Baxter Healthcare | $109.23 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Sanofi-Aventis U.S. LLC | $96.50 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $82.83 | 2021-2022 | |
| Genentech USA, INC. | $49.45 | 2023-2024 | Alecensa, Tecentriq, Rozlytrek |
| Jazz Pharmaceuticals INC. | $45.91 | 2021-2022 | |
| Optinose US, INC. | $37.79 | 2021-2022 | |
| Pfizer INC. | $26.07 | 2024 | |
| Inspire Medical Systems, INC. | $25.80 | 2023 | Inspire |
| Advanced Respiratory, INC | $25.61 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.44 | 2025 | Opdivo |
| Fisher & Paykel Healthcare INC | $17.35 | 2021 | |
| Caris Mpi, INC. | $16.51 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edith Utley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.